Evidence map›Paper›PMID 32267550›Full record

ArticleAlcoholism, clinical and experimental research2020

Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism.

Joshua Silva, Xin Yu, Renita Moradian, Carson Folk, Maximilian H Spatz, Phoebe Kim, Adil A Bhatti, Daryl L Davies, Jing Liang

Open access · hybridAbstract read
In one paragraph

Article in Alcoholism, clinical and experimental research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Joshua SilvaFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.ORCID 0000-0002-2010-729X
Xin YuFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Renita MoradianFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Carson FolkFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Maximilian H SpatzFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Phoebe KimFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Adil A BhattiFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Daryl L DaviesFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
Jing LiangFrom the, Titus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California.
University of Southern California · US

Funding

Regulation of Alcohol Intake by Purinergic P2X4 ReceptorsR01AA022448 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DAVIES, DARYL L · 2013 to 2020
$2.9M
NIAAA NIH HHS R01 AA022448
6 · The paper itself

Abstract

backgroundExcess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis-associated deaths in the United States. EtOH-induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical-induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH-mediated lipid dysregulation, thus promoting hepatocellular health.

methodsThe hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL-17A hepatoblastoma cell models. EtOH-mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD

resultsDHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)-1a, and acetyl CoA carboxylase (ACC)-1. DHM induced expression of EtOH-metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD

conclusionIn total, these findings support the utility of DHM as a dietary supplement to reduce EtOH-induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.

Indexed as

Adenylate KinaseAnimalsDietary SupplementsEnzyme ActivationEthanolFatty Liver, AlcoholicFlavonolsHep G2 CellsHumansLipid MetabolismLiverLiver Diseases, AlcoholicMaleMiceMice, Inbred C57BLTriglyceridesAdenylate KinasedihydromyricetinEthanolFlavonolsTriglyceridesAlcohol Liver DamageDihydromyricetinEthanolSteatosis

Identifiers

PMID32267550
PMCPMC7211127
OpenAlexW3014436063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.